Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer
2019
Autori
Jovanović, DraganaRoksandić-Milenković, Marina
Kotur-Stevuljević, Jelena
Ceriman, Vesna
Vukanić, Ivana
Samardžić, Natalija
Popević, Spasoje
Ilić, Branislav
Gajić, Milija
Simon, Marioara
Simon, Ioan
Spasojević-Kalimanovska, Vesna
Belić, Milica
Mirkov, Damjan
Šumarac, Zorica
Milenković, Vladislav
Članak u časopisu (Objavljena verzija)
Metapodaci
Prikaz svih podataka o dokumentuApstrakt
Background: The objective of this prospective study was to evaluate whether soluble programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) and serum amyloid A1 (SAA1) are potential diagnostic, predictive or prognostic biomarkers in lung cancer. Methods: Lung cancer patients (n=115) with advanced metastatic disease, 101 with non-small cell lung cancer, NSCLC (77 EGFR wild-type NSCLC patients on chemotherapy, 15 EGFR mutation positive adenocarcinoma patients, 9 patients with mPD-L1 Expression >= 50% NSCLC - responders to immunotherapy), and 14 patients with small cell lung cancer (SCLC) were examined. ELISA method was used to determine sPD-L1 and SAA1 concentrations in patients' plasma. Results: Significantly higher blood concentrations of sPD-L1 and SAA1 were noted in lung cancer patients compared with a healthy control group. In PD-L1 + NSCLC patients, a significantly higher sPD-L1 level was noticed compared to any other lung cancer subgroup, as well as the highest average... SAA1 value compared to other subgroups. Conclusions: It seems that sPD-1/PD-L1 might be a potential biomarker, prognostic and/or predictive, particularly in patients treated with immunotherapy. Serum amyloid A1 has potential to act as a good predictor of patients' survival, as well as a biomarker of a more advanced disease, with possibly good capability to predict the course of disease measured at different time points.
Ključne reči:
sPD-L1 / serum amyloid A1 / biomarker / PD-L1 positive NSCLCIzvor:
Journal of Medical Biochemistry, 2019, 38, 3, 332-341Izdavač:
- Društvo medicinskih biohemičara Srbije, Beograd i Versita
Finansiranje / projekti:
- Kliničko epidemiološka istraživanja najčešćih neželjenih događaja tokom bolničkog lečenja (RS-MESTD-Basic Research (BR or ON)-175046)
DOI: 10.2478/jomb-2018-0036
ISSN: 1452-8258
PubMed: 31156344
WoS: 000468363100011
Scopus: 2-s2.0-85057603105
Institucija/grupa
PharmacyTY - JOUR AU - Jovanović, Dragana AU - Roksandić-Milenković, Marina AU - Kotur-Stevuljević, Jelena AU - Ceriman, Vesna AU - Vukanić, Ivana AU - Samardžić, Natalija AU - Popević, Spasoje AU - Ilić, Branislav AU - Gajić, Milija AU - Simon, Marioara AU - Simon, Ioan AU - Spasojević-Kalimanovska, Vesna AU - Belić, Milica AU - Mirkov, Damjan AU - Šumarac, Zorica AU - Milenković, Vladislav PY - 2019 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3341 AB - Background: The objective of this prospective study was to evaluate whether soluble programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) and serum amyloid A1 (SAA1) are potential diagnostic, predictive or prognostic biomarkers in lung cancer. Methods: Lung cancer patients (n=115) with advanced metastatic disease, 101 with non-small cell lung cancer, NSCLC (77 EGFR wild-type NSCLC patients on chemotherapy, 15 EGFR mutation positive adenocarcinoma patients, 9 patients with mPD-L1 Expression >= 50% NSCLC - responders to immunotherapy), and 14 patients with small cell lung cancer (SCLC) were examined. ELISA method was used to determine sPD-L1 and SAA1 concentrations in patients' plasma. Results: Significantly higher blood concentrations of sPD-L1 and SAA1 were noted in lung cancer patients compared with a healthy control group. In PD-L1 + NSCLC patients, a significantly higher sPD-L1 level was noticed compared to any other lung cancer subgroup, as well as the highest average SAA1 value compared to other subgroups. Conclusions: It seems that sPD-1/PD-L1 might be a potential biomarker, prognostic and/or predictive, particularly in patients treated with immunotherapy. Serum amyloid A1 has potential to act as a good predictor of patients' survival, as well as a biomarker of a more advanced disease, with possibly good capability to predict the course of disease measured at different time points. PB - Društvo medicinskih biohemičara Srbije, Beograd i Versita T2 - Journal of Medical Biochemistry T1 - Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer VL - 38 IS - 3 SP - 332 EP - 341 DO - 10.2478/jomb-2018-0036 ER -
@article{ author = "Jovanović, Dragana and Roksandić-Milenković, Marina and Kotur-Stevuljević, Jelena and Ceriman, Vesna and Vukanić, Ivana and Samardžić, Natalija and Popević, Spasoje and Ilić, Branislav and Gajić, Milija and Simon, Marioara and Simon, Ioan and Spasojević-Kalimanovska, Vesna and Belić, Milica and Mirkov, Damjan and Šumarac, Zorica and Milenković, Vladislav", year = "2019", abstract = "Background: The objective of this prospective study was to evaluate whether soluble programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) and serum amyloid A1 (SAA1) are potential diagnostic, predictive or prognostic biomarkers in lung cancer. Methods: Lung cancer patients (n=115) with advanced metastatic disease, 101 with non-small cell lung cancer, NSCLC (77 EGFR wild-type NSCLC patients on chemotherapy, 15 EGFR mutation positive adenocarcinoma patients, 9 patients with mPD-L1 Expression >= 50% NSCLC - responders to immunotherapy), and 14 patients with small cell lung cancer (SCLC) were examined. ELISA method was used to determine sPD-L1 and SAA1 concentrations in patients' plasma. Results: Significantly higher blood concentrations of sPD-L1 and SAA1 were noted in lung cancer patients compared with a healthy control group. In PD-L1 + NSCLC patients, a significantly higher sPD-L1 level was noticed compared to any other lung cancer subgroup, as well as the highest average SAA1 value compared to other subgroups. Conclusions: It seems that sPD-1/PD-L1 might be a potential biomarker, prognostic and/or predictive, particularly in patients treated with immunotherapy. Serum amyloid A1 has potential to act as a good predictor of patients' survival, as well as a biomarker of a more advanced disease, with possibly good capability to predict the course of disease measured at different time points.", publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita", journal = "Journal of Medical Biochemistry", title = "Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer", volume = "38", number = "3", pages = "332-341", doi = "10.2478/jomb-2018-0036" }
Jovanović, D., Roksandić-Milenković, M., Kotur-Stevuljević, J., Ceriman, V., Vukanić, I., Samardžić, N., Popević, S., Ilić, B., Gajić, M., Simon, M., Simon, I., Spasojević-Kalimanovska, V., Belić, M., Mirkov, D., Šumarac, Z.,& Milenković, V.. (2019). Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer. in Journal of Medical Biochemistry Društvo medicinskih biohemičara Srbije, Beograd i Versita., 38(3), 332-341. https://doi.org/10.2478/jomb-2018-0036
Jovanović D, Roksandić-Milenković M, Kotur-Stevuljević J, Ceriman V, Vukanić I, Samardžić N, Popević S, Ilić B, Gajić M, Simon M, Simon I, Spasojević-Kalimanovska V, Belić M, Mirkov D, Šumarac Z, Milenković V. Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer. in Journal of Medical Biochemistry. 2019;38(3):332-341. doi:10.2478/jomb-2018-0036 .
Jovanović, Dragana, Roksandić-Milenković, Marina, Kotur-Stevuljević, Jelena, Ceriman, Vesna, Vukanić, Ivana, Samardžić, Natalija, Popević, Spasoje, Ilić, Branislav, Gajić, Milija, Simon, Marioara, Simon, Ioan, Spasojević-Kalimanovska, Vesna, Belić, Milica, Mirkov, Damjan, Šumarac, Zorica, Milenković, Vladislav, "Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer" in Journal of Medical Biochemistry, 38, no. 3 (2019):332-341, https://doi.org/10.2478/jomb-2018-0036 . .